New UM Clinical Trial Will Evaluate Platelet-Rich Plasma for Treating Erectile Dysfunction
A new clinical trial at the University of Miami Miller School of Medicine will examine the use of platelet-rich plasma (PRP) for treating erectile dysfunction – one of the first such controlled studies in the United States to start enrolling patients.
Unlike current treatments, which focus on treating symptoms, PRP is a regenerative therapy. Injections of PRP from the individual’s body may offer a potential cure for the underlying disease in some patients.”
The UM clinical trial is designed to test both the safety and effectiveness of PRP injections. It is a double blind, randomized study in which 40 of the 80 participants will receive PRP from their own blood, and 40 will receive a placebo.
Participants with diabetes- or vascular-related erectile dysfunction will be recruited for the trial and followed for six months. However, individuals with underlying nerve or neurological conditions, such as a loss of sensation in the penis, would not be eligible.
To address COVID-19 safety concerns, the University of Miami is taking precautions for clinical trial participants, as well as patients, to receive care in a safe environment. Examination rooms are carefully disinfected, and doctors and nurses wear personal protective equipment such as goggles, gloves, and facemasks. Non-COVID patients are kept in areas separate from COVID-19 patients and anyone with a suspected case of coronavirus is treated in an isolated area.